Literature DB >> 8849947

Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes.

R S Freedman1, C D Platsoucas.   

Abstract

Surgery and chemotherapy have contributed to a modest overall survival in patients with epithelial ovarian carcinoma. It is therefore important to pursue novel therapy strategies for this disease that are different from conventional chemotherapy. Tumor infiltrating lymphocytes (TILs) from patients with ovarian carcinoma may represent an active immune response of the host directed against the tumor cells. These TILs can be expanded in vitro in low concentrations of recombinant interleukin-2 (rIL-2) by a few thousandfold. The resulting T-cell lines comprise CD3+CD4+TCR alpha beta + or CD3+CD8+TCR alpha beta + cells, or mixtures of both. These T-cell lines may exhibit either tumor-specific cytotoxicity against autologous tumor cells, or produce cytokines (interferon-gamma, tumor necrosis factor, and granulocyte stimulating factor) either in antigen-dependent (tumor-specific) or an antigen-independent manner. T-cell lines exhibiting primarily autologous tumor-specific cytotoxicity were developed from approximately 50% of the patients. Blocking experiments using appropriate monoclonal antibodies revealed that the CD3/TCR complex on the effector cells and the MHC class I antigens on the tumor cells were involved in the cytolytic process. We have developed a four-step method for the expansion of TILs to large numbers (1 x 10(10) to 1 x 10(11)) sufficient for clinical trials in patients with ovarian cancer. We have conducted a pilot clinical trial to examine the feasibility and clinical effects of intraperitoneal TILs and low-dose rIL-2 in patients with advanced ovarian carcinoma who were refractory to platinum-based chemotherapy. More recently, procedures have been developed for obtaining large numbers of purified CD8+ rIL-2-expanded TILs for the treatment of patients with ovarian carcinoma. The evolution of clinical trials and correlative studies necessary to develop an effective adoptive immunotherapy approach were discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8849947     DOI: 10.1007/978-1-4613-1247-5_8

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN: 0927-3042


  15 in total

Review 1.  Immunotherapeutic approaches for the treatment of breast cancer.

Authors:  K L Knutson; K Schiffman; K Rinn; M L Disis
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

Review 2.  B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look.

Authors:  Jenessa B Smith; Caitlin Stashwick; Daniel J Powell
Journal:  Gynecol Oncol       Date:  2014-03-20       Impact factor: 5.482

3.  Anticancer immune reactivity and long-term survival after treatment of metastatic ovarian cancer with dendritic cells.

Authors:  Samuel D Bernal; Enrique T Ona; Aileen Riego-Javier; Romulo DE Villa; Gloria R Cristal-Luna; Josephine B Laguatan; Eunice R Batac; Oscar Q Canlas
Journal:  Oncol Lett       Date:  2011-09-20       Impact factor: 2.967

4.  A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.

Authors:  Michael H Kershaw; Jennifer A Westwood; Linda L Parker; Gang Wang; Zelig Eshhar; Sharon A Mavroukakis; Donald E White; John R Wunderlich; Silvana Canevari; Linda Rogers-Freezer; Clara C Chen; James C Yang; Steven A Rosenberg; Patrick Hwu
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

5.  CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor.

Authors:  Qunrui Ye; De-Gang Song; Mathilde Poussin; Tori Yamamoto; Andrew Best; Chunsheng Li; George Coukos; Daniel J Powell
Journal:  Clin Cancer Res       Date:  2013-09-17       Impact factor: 12.531

6.  Cellular distribution of retinoic acid receptor-alpha protein in serous adenocarcinomas of ovarian, tubal, and peritoneal origin: comparison with estrogen receptor status.

Authors:  C D Katsetos; I Stadnicka; J C Boyd; H Ehya; S Zheng; C M Soprano; H S Cooper; A S Patchefsky; D R Soprano; K J Soprano
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

Review 7.  Tumor-infiltrating lymphocytes for the treatment of metastatic cancer.

Authors:  M H Geukes Foppen; M Donia; I M Svane; J B A G Haanen
Journal:  Mol Oncol       Date:  2015-10-30       Impact factor: 6.603

Review 8.  Cellular immunotherapy for ovarian cancer.

Authors:  Martin J Cannon; Timothy J O'Brien
Journal:  Expert Opin Biol Ther       Date:  2009-06       Impact factor: 4.388

9.  Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumour-infiltrating lymphocyte (TIL)-derived T cell lines and established tumour cell lines.

Authors:  M A Nash; R Lenzi; C L Edwards; J J Kavanagh; A P Kudelka; C F Verschraegen; C D Platsoucas; R S Freedman
Journal:  Clin Exp Immunol       Date:  1998-05       Impact factor: 4.330

10.  Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer.

Authors:  Sarah F Adams; Douglas A Levine; Mark G Cadungog; Rachel Hammond; Andrea Facciabene; Narciso Olvera; Stephen C Rubin; Jeff Boyd; Phyllis A Gimotty; George Coukos
Journal:  Cancer       Date:  2009-07-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.